Artificial intelligence (AI) has the potential to reshape the pharmaceutical industry, potentially cutting drug development time by up to 70% and reducing the number of clinical trial phases ...

Keep in mind that nearly all U.S. imports of medicines have been duty-free since 1994 under the World Trade Organization’s Pharmaceutical Agreement. New tariffs will wreak havoc on ...

The chief executive of AstraZeneca (AZN.L), opens new tab said on Tuesday that the drugmaker will maintain its 2025 sales guidance even if the U.S. levies tariffs on pharma products made in the ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a positive phase 3 readout. Akeso's bispecific ivonescimab has bagged a ...

LONDON (Reuters) -A 25% U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, boosting U.S. prices by as much as 12.9% if passed on, a report ...

German pharmaceutical company Merck announced Monday that it has reached an agreement to acquire US-based SpringWorks Therapeutics for $3.9 billion, a move aimed at strengthening its oncology ...

The science sector is composed of a wide range of pharmaceutical and life sciences multinationals which are exposed to potential sector specific trade tariffs. The cautious hiring sentiment was ...

Donald Trump’s threat of placing 25 percent tariffs on all foreign pharmaceutical imports would increase U.S. drug costs by nearly $51 billion, a new report has found. Prices of medication and ...

Pharma stocks rally on Trump's tariff pause, led by up to 7% surge in Laurus Labs, Granules, Cipla Apr 11 2025 05:21 PM Stocks to Watch Today: TCS, Biocon, GAIL, Greaves Cotton, Sun Pharma ...

PHARMA EARNINGS NOD TO TARIFFS — Major drug companies are beginning to deliver their first-quarter readouts to Wall Street analysts, revealing their expectations of how a global tariff war could ...

Regeneron has since re-filed the BCMAxCD3 drug in the U.S., and it's now awaiting a July 10 decision target date. With linvoseltamab's delayed arrival in the U.S., the multiple myeloma bispecific ...